The health department reported that there are already seven patients who have tested positive for mpox.
It stated that all of the patients who had tested positive had long-term conditions like HIV, indicating a substantial risk of immunocompromised individuals if treatment is not followed as directed.
A 39-year-old male who was taken on May 28 to a nearby private medical facility in Cape Town is the most recent confirmed instance. At a private laboratory on Thursday, the man’s Mpox test result was positive.
According to the department, the patient had numerous lesions when they first arrived, was positive for RVD, and had an unclear CD4 level.
Foster Mohale, a department spokesperson, stated that the most recent patient “listed his residential address as Northcliff, Gauteng, just like case number six.”
In order to reduce the danger of major health issues in the event that they catch Mpox or other infections, the department recommended persons taking medicine for any health condition to follow their doctor’s instructions.
“Misusing your prescriptions can have a detrimental impact on your quality of life, and treatment noncompliance can prevent new or worsening health problems,” he stated.
He noted that Tecovirimat, which has been shown to be useful in reducing Mpox-related morbidity and mortality, particularly when started within a few days of incubation and diagnosis, will be sent to the department in a batch.
Four cases were reported in KwaZulu-Natal, two in Gauteng, and one in Cape Town, according to the department. The second death was reported from a hospital in uMgungundlovu, KwaZulu-Natal, and the first was reported from Tembisa Hospital in Gauteng.
In order to assess the disease’s burden and provide the public with the knowledge they need to make educated health decisions, Mohale stated that the agency was collaborating closely with other relevant parties and will keep up its surveillance, contract tracing, and health education efforts across the nation.
He stated, “The cooperation and accuracy of information provided by both confirmed and suspected cases depends on the effectiveness of contract tracing and case finding.”
Common signs and symptoms of Mpox include fever, headache, muscle aches, back discomfort, swelling glands (lymph nodes), and a rash that can linger for two to four weeks.
The excruciating rash, which can affect the face, hands, feet, groin, genital, and/or anal areas, appears as blisters or ulcers.
